Exchange: NASDAQ·Updated 07:30 PM EST

ALMS News

News
all
press releases
FY2026 Earnings Forecast for Alumis Issued By HC Wainwright
Alumis Inc. (NASDAQ:ALMS - Free Report) - Equities research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Alumis in a research note issued to investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($3...
MarketBeat
FY2026 Earnings Forecast for Alumis Issued By HC Wainwright
Alumis Inc. (NASDAQ:ALMS - Free Report) - Equities research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Alumis in a research note issued to investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($3...
MarketBeat
More News
Alumis (NASDAQ:ALMS) Hits New 1-Year Low on Analyst Downgrade...
MarketBeat
Oppenheimer decreased their target price on shares of Alumis to $28.00 and set an "outperform" rating for the company in a research note on Monday...
MarketBeat
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +44.44% and +3.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Analysts upgraded Alumis, Sirius XM, OGE Energy, revising their price targets and outlooks.read more...
Benzinga
The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues.
Stocktwits
Alumis (ALMS) stock drops over 50% after Phase 2b lupus trial misses overall endpoints, but sub-group data shows promise.read more...
Benzinga
Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.read more...
Benzinga
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Zacks
Prothena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.